Neoral (cyclosporine) labeling for psoriasis recommends biweekly creatinine, hypertension monitoring.
Executive Summary
NOVARTIS NEORAL PSORIASIS PATIENT BIWEEKLY CREATININE, BLOOD PRESSURE MONITORING recommended for the first three months of treatment, revised labeling states. Monitoring of blood urea nitrogen, complete blood count, uric acid, potassium, lipids and magnesium is also recommended biweekly for the first three months of psoriasis therapy, labeling states. Monthly monitoring is appropriate after the first three months of therapy, labeling adds. FDA approved the new indication for cyclosporine in June and Novartis expects to begin promoting the use by the end of the year ("The Pink Sheet" June 30, T&G-1).